SWTX Valuation

SpringWorks Therapeutics Inc

Add to Watchlist

Advanced Chart

46.980

-0.01(-0.021%)1D

Overview
Forecast
Valuation
Earnings

SWTX Relative Valuation

SWTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SWTX is overvalued; if below, it's undervalued.

Historical Valuation

SpringWorks Therapeutics Inc (SWTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.27 is considered Undervalued compared with the five-year average of -15.93. The fair price of SpringWorks Therapeutics Inc (SWTX) is between 330.26 to 339.80 according to relative valuation methord. Compared to the current price of 46.98 USD , SpringWorks Therapeutics Inc is Undervalued By 85.77%.

Relative Value

Fair Zone

330.26-339.80

Current Price：46.98

85.77%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

8.40

P/B

Median3y

4.63

Median5y

5.57

-4.80

FCF Yield

Median3y

-9.37

Median5y

-6.95

Competitors Valuation Multiple

The average P/S ratio for SWTX's competitors is 254.94, providing a benchmark for relative valuation. SpringWorks Therapeutics Inc Corp (SWTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 133.68%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SWTX.O

SpringWorks Therapeutics Inc

Loss

Average P/S: 254.94

133.68%